Caen

Running trials

• Recruiting

  A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

  NCT07498426· Phase 3· Source

• Active, not recruiting

  Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

  NCT06092879· Source

• Recruiting

  Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

  NCT05948943· Phase 2/3· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Source

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

  NCT03822468· Phase 2· Source

• Completed

  Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

  NCT03056755· Phase 2· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Source

• Completed

  LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

  NCT01828099· Phase 3· Source

• Completed

  LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

  NCT01828112· Phase 3· Source